PMOS: the new name for PCOS
Key Takeaways
Polyendocrine metabolic ovarian syndrome (PMOS) is the new consensus name for what was long called polycystic ovary syndrome (PCOS). The rename drops the misleading focus on ovarian cysts; the 2023 care recommendations themselves did not change. For diagnosis, metabolic screening, letrozole, pregnancy and IVF safety, see the full PCOS/PMOS guide.
Key evidence: Lancet — PMOS naming consensus (2026) 2023 International Evidence-based Guideline (Teede et al.) ASRM — PMOS naming & 2023 recommendations
What changed — and what did not
PMOS stands for polyendocrine metabolic ovarian syndrome. It is the new name selected through a global consensus process and endorsed by leading international professional organisations — not merely a suggestion — for the condition previously called polycystic ovary syndrome (PCOS).
Patients, laboratories and health systems still use PCOS widely. In titles and search-facing text, PCOS / PMOS belong together for now. After first mention, many clinical texts say PMOS (formerly PCOS), then PMOS.
PMOS is the same clinical picture previously called PCOS; the name has changed, and a previous diagnosis and treatment plan remain valid. Diagnostic criteria and the 2023 care recommendations did not change with the rename. A roughly three-year transition is planned, with fuller integration into the expected 2028 international guideline.
This page explains the rename. The full clinical guide — diagnosis, AMH, metformin, letrozole, pregnancy and IVF — is here: PCOS, now called PMOS: diagnosis, treatment and fertility.
What is PMOS?
PMOS is the new name for PCOS, not a separate diagnosis. A 2026 global consensus process published in The Lancet selected “polyendocrine metabolic ovarian syndrome” because it describes the condition more accurately.
The words matter:
- Polyendocrine — several hormone systems, including androgens, insulin, gonadotropins and ovarian hormones
- Metabolic — insulin resistance, dysglycaemia, lipids, weight-related risk, sleep apnoea and long-term cardiometabolic health
- Ovarian — the reproductive and ovulatory part stays visible, without implying that pathological cysts are the centre of the problem
Why was “PCOS” misleading?
The old name suggests that ovarian cysts define the condition. That is not accurate. Ultrasound often shows many small follicles — not the kind of cysts people usually fear.
That wording caused practical problems. Some patients were told they could not have PCOS because their ovaries did not look “polycystic.” Others worried they needed surgery for cystic disease. In adults, diagnosis can rest on ovulatory dysfunction and hyperandrogenism even when polycystic ovarian morphology is absent or has not been assessed. Metabolic features shape health risks and management, but they are not diagnostic criteria.
The new name reduces that confusion and makes room for what patients often feel most: irregular cycles, acne or hirsutism, difficulty ovulating, insulin resistance, weight change, anxiety about fertility and pregnancy risks.
Did the diagnostic criteria change?
No. The rename does not, by itself, change diagnosis. Adult care still follows the 2023 international evidence-based guideline: after excluding other causes, two of three features are generally needed — ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound or, in adults, AMH used as an alternative to ultrasound for that morphological criterion.
A few points that matter during the name transition:
- AMH is not a stand-alone diagnostic test, and there is no universal cut-off for every assay and population
- Ultrasound and AMH should not routinely be used together for the same morphological criterion
- In adolescents, firm diagnosis needs both persistent irregularity (by years since menarche) and hyperandrogenism; ultrasound and AMH are not recommended for diagnosis within eight years of menarche
If your previous diagnosis was PCOS, the new terminology does not erase it. It reframes the same condition.
What does PMOS mean for fertility and IVF?
For fertility care, the name is a reminder to assess ovulation, hormones and metabolic health together — not cysts alone. Many people with PMOS have a high antral follicle count or AMH level but irregular or absent ovulation. These findings do not, by themselves, indicate egg quality or guarantee fertility. Others ovulate and still need metabolic or androgen-focused care before pregnancy.
Glycaemic status should be assessed at diagnosis regardless of BMI; a 75 g OGTT is the most accurate test in this condition. IVF principles do not change because of the new name: stimulation should be individualised, and OHSS risk actively reduced (antagonist protocols, cautious dosing, agonist trigger and freeze-all when the whole picture warrants it).
Detail on workup, letrozole, pregnancy and IVF sits in the full PCOS/PMOS guide. If another endocrine condition is present — for example hyperprolactinaemia — it should be identified rather than assuming every irregular cycle is PMOS.
What should patients do during the transition?
You do not need to repeat your entire workup just because the name changed. A previous PCOS diagnosis remains clinically meaningful. At the next visit, useful questions include:
- Which features do I have: ovulatory dysfunction, hyperandrogenism, ultrasound/AMH findings, or a combination?
- Have other causes of irregular cycles or high androgens been excluded — including pregnancy when relevant?
- Do I need metabolic screening, especially before pregnancy or fertility treatment?
- If I am trying to conceive, should we start with ovulation induction or consider IVF?
- If IVF is needed, what is the OHSS prevention plan?
The best use of the new name is not cosmetic. It is a prompt to keep the care plan broader and more precise.
FAQ
Is PMOS the same as PCOS?
Yes. PMOS is the new consensus name for the condition historically called PCOS. Many documents will use both names for a while.
Does the new name mean ovarian cysts are not important?
It means they were never the whole story. The ultrasound pattern can still help adult diagnosis, but PMOS is not defined by harmful cysts. Hormonal and metabolic features are central.
Will my old PCOS diagnosis still be accepted?
Yes. Medical systems may take time to adopt PMOS on forms and coding. Clinically, a previous PCOS diagnosis remains relevant.
Does PMOS always cause infertility?
No. Many people conceive naturally, especially if they ovulate regularly. When ovulation is irregular, ovulation induction or IVF may be used depending on age, duration of infertility, semen analysis, tubal status and previous treatment.
Is PMOS mainly a weight-related condition?
No. It can occur at any body size. Weight and insulin resistance can influence severity in some patients, but they do not explain every case.
Should treatment be different now?
Treatment still follows evidence-based PCOS/PMOS care. The name change improves accuracy; it does not replace clinical judgement. See the full guide for diagnosis and treatment detail.
Dr. Aksoy’s approach
In consultation, the most useful part of this rename is the conversation it opens. When a patient hears “polycystic,” she often imagines cysts that need removing. When we explain PMOS, we can talk about ovulation, androgens, insulin resistance and IVF safety more accurately. The name is new; the need for careful, individualised assessment is the same.
Sources
- Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329–2339. doi:10.1016/S0140-6736(26)00717-8. PMID: 42119588.
- Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril 2023;120(4):767–793. doi:10.1016/j.fertnstert.2023.07.025. PMID: 37589624.
- ASRM. PCOS is now PMOS: understanding the name change. May 27, 2026.
- ASRM. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polyendocrine Metabolic Ovarian Syndrome (2023).
- Monash University. International evidence-based guideline for PMOS / PCOS.
- WHO. Polycystic ovary syndrome.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 2004;19(1):41–47.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.